

SENATE

STATE OF MINNESOTA

NINETY-FIRST SESSION

S.F. No. 1470

(SENATE AUTHORS: LIMMER, Ingebrigtsen and Benson)		
DATE	D-PG	OFFICIAL STATUS
02/18/2019	441	Introduction and first reading Referred to Judiciary and Public Safety Finance and Policy
03/07/2019	715	Author added Benson
03/13/2019	846a	Comm report: To pass as amended and re-refer to Health and Human Services Finance and Policy
03/02/2020	5093a	Comm report: To pass as amended
	5112	Second reading See SF13, Art. 5

1.1

A bill for an act

1.2

relating to public safety; modifying the schedules of controlled substances;

1.3

amending Minnesota Statutes 2018, section 152.02, subdivisions 2, 3, 4.

1.4

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.5

Section 1. Minnesota Statutes 2018, section 152.02, subdivision 2, is amended to read:

1.6

Subd. 2. **Schedule I.** (a) Schedule I consists of the substances listed in this subdivision.

1.7

(b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the

1.8

following substances, including their analogs, isomers, esters, ethers, salts, and salts of

1.9

isomers, esters, and ethers, whenever the existence of the analogs, isomers, esters, ethers,

1.10

and salts is possible:

1.11

(1) acetylmethadol;

1.12

(2) allylprodine;

1.13

(3) alphacetylmethadol (except levo-alphacetylmethadol, also known as levomethadyl

1.14

acetate);

1.15

(4) alphameprodine;

1.16

(5) alphamethadol;

1.17

(6) alpha-methylfentanyl benzethidine;

1.18

(7) betacetylmethadol;

1.19

(8) betameprodine;

1.20

(9) betamethadol;

- 2.1 (10) betaprodine;
- 2.2 (11) clonitazene;
- 2.3 (12) dextromoramide;
- 2.4 (13) diampromide;
- 2.5 (14) diethylambutene;
- 2.6 (15) difenoxin;
- 2.7 (16) dimenoxadol;
- 2.8 (17) dimepheptanol;
- 2.9 (18) dimethylambutene;
- 2.10 (19) dioxaphetyl butyrate;
- 2.11 (20) dipipanone;
- 2.12 (21) ethylmethylthiambutene;
- 2.13 (22) etonitazene;
- 2.14 (23) etoxeridine;
- 2.15 (24) furethidine;
- 2.16 (25) hydroxypethidine;
- 2.17 (26) ketobemidone;
- 2.18 (27) levomoramide;
- 2.19 (28) levophenacylmorphane;
- 2.20 (29) 3-methylfentanyl;
- 2.21 (30) acetyl-alpha-methylfentanyl;
- 2.22 (31) alpha-methylthiofentanyl;
- 2.23 (32) benzylfentanyl beta-hydroxyfentanyl;
- 2.24 (33) beta-hydroxy-3-methylfentanyl;
- 2.25 (34) 3-methylthiofentanyl;
- 2.26 (35) thenylfentanyl;
- 2.27 (36) thiofentanyl;

- 3.1 (37) para-fluorofentanyl;
- 3.2 (38) morpheridine;
- 3.3 (39) 1-methyl-4-phenyl-4-propionoxypiperidine;
- 3.4 (40) noracymethadol;
- 3.5 (41) norlevorphanol;
- 3.6 (42) normethadone;
- 3.7 (43) norpipanone;
- 3.8 (44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);
- 3.9 (45) phenadoxone;
- 3.10 (46) phenampromide;
- 3.11 (47) phenomorphan;
- 3.12 (48) phenoperidine;
- 3.13 (49) piritramide;
- 3.14 (50) proheptazine;
- 3.15 (51) properidine;
- 3.16 (52) propiram;
- 3.17 (53) racemoramide;
- 3.18 (54) tilidine;
- 3.19 (55) trimeperidine;
- 3.20 (56) N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl);
- 3.21 (57) 3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-
- 3.22 methylbenzamide(U47700);
- 3.23 (58) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide(furanylfentanyl);
- 3.24 ~~and~~
- 3.25 (59) 4-(4-bromophenyl)-4-dimethylamino-1-phenethylcyclohexanol (bromadol);
- 3.26 (60) N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide (Cyclopropyl
- 3.27 fentanyl);
- 3.28 (61) N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide) (butyryl fentanyl);

4.1 (62) 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine) (MT-45);

4.2 (63) N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide (cyclopentyl
4.3 fentanyl);

4.4 (64) N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide (isobutyryl fentanyl);

4.5 (65) N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide (valeryl fentanyl);

4.6 (66) N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide
4.7 (para-chloroisobutyryl fentanyl);

4.8 (67) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide (para-fluorobutyryl
4.9 fentanyl);

4.10 (68) N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide
4.11 (para-methoxybutyryl fentanyl);

4.12 (69) N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide (ocfentanil);

4.13 (70) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide (4-fluoroisobutyryl
4.14 fentanyl or para-fluoroisobutyryl fentanyl);

4.15 (71) N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryl fentanyl or
4.16 acryloylfentanyl);

4.17 (72) 2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (methoxyacetyl
4.18 fentanyl);

4.19 (73) N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (ortho-fluorofentanyl
4.20 or 2-fluorofentanyl);

4.21 (74) N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide
4.22 (tetrahydrofuranyl fentanyl); and

4.23 (75) Fentanyl-related substances, their isomers, esters, ethers, salts and salts of isomers,
4.24 esters and ethers, meaning any substance not otherwise listed under another federal
4.25 Administration Controlled Substance Code Number or not otherwise listed in this section,
4.26 and for which no exemption or approval is in effect under section 505 of the Federal Food,
4.27 Drug, and Cosmetic Act, United States Code , title 21, section 355, that is structurally related
4.28 to fentanyl by one or more of the following modifications:

4.29 (i) replacement of the phenyl portion of the phenethyl group by any monocycle, whether
4.30 or not further substituted in or on the monocycle;

5.1 (ii) substitution in or on the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl, halo,
5.2 haloalkyl, amino, or nitro groups;

5.3 (iii) substitution in or on the piperidine ring with alkyl, alkenyl, alkoxyl, ester, ether,
5.4 hydroxyl, halo, haloalkyl, amino, or nitro groups;

5.5 (iv) replacement of the aniline ring with any aromatic monocycle whether or not further
5.6 substituted in or on the aromatic monocycle; or

5.7 (v) replacement of the N-propionyl group by another acyl group.

5.8 (c) Opium derivatives. Any of the following substances, their analogs, salts, isomers,
5.9 and salts of isomers, unless specifically excepted or unless listed in another schedule,
5.10 whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:

5.11 (1) acetorphine;

5.12 (2) acetyldihydrocodeine;

5.13 (3) benzylmorphine;

5.14 (4) codeine methylbromide;

5.15 (5) codeine-n-oxide;

5.16 (6) cyprenorphine;

5.17 (7) desomorphine;

5.18 (8) dihydromorphine;

5.19 (9) drotebanol;

5.20 (10) etorphine;

5.21 (11) heroin;

5.22 (12) hydromorphenol;

5.23 (13) methyl-desorphine;

5.24 (14) methyldihydromorphine;

5.25 (15) morphine methylbromide;

5.26 (16) morphine methylsulfonate;

5.27 (17) morphine-n-oxide;

5.28 (18) myrophine;

- 6.1 (19) nicocodeine;
- 6.2 (20) nicomorphine;
- 6.3 (21) normorphine;
- 6.4 (22) pholcodine; and
- 6.5 (23) thebacon.

6.6 (d) Hallucinogens. Any material, compound, mixture or preparation which contains any
6.7 quantity of the following substances, their analogs, salts, isomers (whether optical, positional,
6.8 or geometric), and salts of isomers, unless specifically excepted or unless listed in another
6.9 schedule, whenever the existence of the analogs, salts, isomers, and salts of isomers is
6.10 possible:

- 6.11 (1) methylenedioxy amphetamine;
- 6.12 (2) methylenedioxymethamphetamine;
- 6.13 (3) methylenedioxy-N-ethylamphetamine (MDEA);
- 6.14 (4) n-hydroxy-methylenedioxyamphetamine;
- 6.15 (5) 4-bromo-2,5-dimethoxyamphetamine (DOB);
- 6.16 (6) 2,5-dimethoxyamphetamine (2,5-DMA);
- 6.17 (7) 4-methoxyamphetamine;
- 6.18 (8) 5-methoxy-3, 4-methylenedioxyamphetamine;
- 6.19 (9) alpha-ethyltryptamine;
- 6.20 (10) bufotenine;
- 6.21 (11) diethyltryptamine;
- 6.22 (12) dimethyltryptamine;
- 6.23 (13) 3,4,5-trimethoxyamphetamine;
- 6.24 (14) 4-methyl-2, 5-dimethoxyamphetamine (DOM);
- 6.25 (15) ibogaine;
- 6.26 (16) lysergic acid diethylamide (LSD);
- 6.27 (17) mescaline;
- 6.28 (18) parahexyl;

- 7.1 (19) N-ethyl-3-piperidyl benzilate;
- 7.2 (20) N-methyl-3-piperidyl benzilate;
- 7.3 (21) psilocybin;
- 7.4 (22) psilocyn;
- 7.5 (23) tenocyclidine (TPCP or TCP);
- 7.6 (24) N-ethyl-1-phenyl-cyclohexylamine (PCE);
- 7.7 (25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy);
- 7.8 (26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);
- 7.9 (27) 4-chloro-2,5-dimethoxyamphetamine (DOC);
- 7.10 (28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);
- 7.11 (29) 4-iodo-2,5-dimethoxyamphetamine (DOI);
- 7.12 (30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B);
- 7.13 (31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);
- 7.14 (32) 4-methyl-2,5-dimethoxyphenethylamine (2C-D);
- 7.15 (33) 4-ethyl-2,5-dimethoxyphenethylamine (2C-E);
- 7.16 (34) 4-iodo-2,5-dimethoxyphenethylamine (2C-I);
- 7.17 (35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);
- 7.18 (36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);
- 7.19 (37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);
- 7.20 (38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine
- 7.21 (2-CB-FLY);
- 7.22 (39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);
- 7.23 (40) alpha-methyltryptamine (AMT);
- 7.24 (41) N,N-diisopropyltryptamine (DiPT);
- 7.25 (42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);
- 7.26 (43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);
- 7.27 (44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);

- 8.1 (45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);
- 8.2 (46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);
- 8.3 (47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
- 8.4 (48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);
- 8.5 (49) 5-methoxy- α -methyltryptamine (5-MeO-AMT);
- 8.6 (50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
- 8.7 (51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);
- 8.8 (52) 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT);
- 8.9 (53) 5-methoxy- α -ethyltryptamine (5-MeO-AET);
- 8.10 (54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);
- 8.11 (55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);
- 8.12 (56) 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT);
- 8.13 (57) methoxetamine (MXE);
- 8.14 (58) 5-iodo-2-aminoindane (5-IAI);
- 8.15 (59) 5,6-methylenedioxy-2-aminoindane (MDAI);
- 8.16 (60) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe);
- 8.17 (61) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe);
- 8.18 (62) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe);
- 8.19 (63) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
- 8.20 (64) 2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2);
- 8.21 (65) N,N-Dipropyltryptamine (DPT);
- 8.22 (66) 3-[1-(Piperidin-1-yl)cyclohexyl]phenol (3-HO-PCP);
- 8.23 (67) N-ethyl-1-(3-methoxyphenyl)cyclohexanamine (3-MeO-PCE);
- 8.24 (68) 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo);
- 8.25 (69) 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine (methoxydine, 4-MeO-PCP);
- 8.26 (70) 2-(2-Chlorophenyl)-2-(ethylamino)cyclohexan-1-one (N-Ethylorketamine,
- 8.27 ethketamine, NENK);

9.1 (71) methylenedioxy-N,N-dimethylamphetamine (MDDMA);

9.2 (72) 3-(2-Ethyl(methyl)aminoethyl)-1H-indol-4-yl (4-AcO-MET); and

9.3 (73) 2-Phenyl-2-(methylamino)cyclohexanone (deschloroketamine).

9.4 (e) Peyote. All parts of the plant presently classified botanically as *Lophophora williamsii*
9.5 Lemaire, whether growing or not, the seeds thereof, any extract from any part of the plant,
9.6 and every compound, manufacture, salts, derivative, mixture, or preparation of the plant,
9.7 its seeds or extracts. The listing of peyote as a controlled substance in Schedule I does not
9.8 apply to the nondrug use of peyote in bona fide religious ceremonies of the American Indian
9.9 Church, and members of the American Indian Church are exempt from registration. Any
9.10 person who manufactures peyote for or distributes peyote to the American Indian Church,
9.11 however, is required to obtain federal registration annually and to comply with all other
9.12 requirements of law.

9.13 (f) Central nervous system depressants. Unless specifically excepted or unless listed in
9.14 another schedule, any material compound, mixture, or preparation which contains any
9.15 quantity of the following substances, their analogs, salts, isomers, and salts of isomers
9.16 whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:

9.17 (1) mecloqualone;

9.18 (2) methaqualone;

9.19 (3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;

9.20 (4) flunitrazepam; ~~and~~

9.21 (5) 2-(2-Methoxyphenyl)-2-(methylamino)cyclohexanone (2-MeO-2-deschloroketamine,
9.22 methoxyketamine);

9.23 (6) tianeptine;

9.24 (7) clonazepam;

9.25 (8) etizolam;

9.26 (9) flubromazepam; and

9.27 (10) flubromazepam.

9.28 (g) Stimulants. Unless specifically excepted or unless listed in another schedule, any
9.29 material compound, mixture, or preparation which contains any quantity of the following
9.30 substances, their analogs, salts, isomers, and salts of isomers whenever the existence of the
9.31 analogs, salts, isomers, and salts of isomers is possible:

- 10.1 (1) aminorex;
- 10.2 (2) cathinone;
- 10.3 (3) fenethylamine;
- 10.4 (4) methcathinone;
- 10.5 (5) methylaminorex;
- 10.6 (6) N,N-dimethylamphetamine;
- 10.7 (7) N-benzylpiperazine (BZP);
- 10.8 (8) methylmethcathinone (mephedrone);
- 10.9 (9) 3,4-methylenedioxy-N-methylcathinone (methyldone);
- 10.10 (10) methoxymethcathinone (methedrone);
- 10.11 (11) methylenedioxypyrovalerone (MDPV);
- 10.12 (12) 3-fluoro-N-methylcathinone (3-FMC);
- 10.13 (13) methylethcathinone (MEC);
- 10.14 (14) 1-benzofuran-6-ylpropan-2-amine (6-APB);
- 10.15 (15) dimethylmethcathinone (DMMC);
- 10.16 (16) fluoroamphetamine;
- 10.17 (17) fluoromethamphetamine;
- 10.18 (18) α -methylaminobutyrophenone (MABP or buphedrone);
- 10.19 (19) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone);
- 10.20 (20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);
- 10.21 (21) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl) pentan-1-one (naphthylpyrovalerone or
- 10.22 naphyrone);
- 10.23 (22) (alpha-pyrrolidinopentiophenone (alpha-PVP);
- 10.24 (23) (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone (4-Me-PHP or MPHP);
- 10.25 (24) 2-(1-pyrrolidinyl)-hexanophenone (Alpha-PHP);
- 10.26 (25) 4-methyl-N-ethylcathinone (4-MEC);
- 10.27 (26) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP);

- 11.1 (27) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
- 11.2 (28) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone);
- 11.3 (29) 4-fluoro-N-methylcathinone (4-FMC);
- 11.4 (30) 3,4-methylenedioxy-N-ethylcathinone (ethylone);
- 11.5 (31) alpha-pyrrolidinobutiophenone (α -PBP);
- 11.6 (32) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB);
- 11.7 (33) 1-phenyl-2-(1-pyrrolidiny)-1-heptanone (PV8);
- 11.8 (34) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB);
- 11.9 (35) 4-methyl-alpha-ethylaminopentiophenone (4-MEAPP);
- 11.10 (36) 4'-chloro-alpha-pyrrolidinopropiophenone (4'-chloro-PPP);
- 11.11 (37) 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)butan-1-one (dibutylone, bk-DMBDB);
- 11.12 (38) 1-(3-chlorophenyl) piperazine (meta-chlorophenylpiperazine or mCPP); ~~and~~
- 11.13 (39) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one (N-ethylpentylone, ephylone);
- 11.14 and
- 11.15 (40) any other substance, except bupropion or compounds listed under a different
- 11.16 schedule, that is structurally derived from 2-aminopropan-1-one by substitution at the
- 11.17 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the
- 11.18 compound is further modified in any of the following ways:
- 11.19 (i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy,
- 11.20 haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring
- 11.21 system by one or more other univalent substituents;
- 11.22 (ii) by substitution at the 3-position with an acyclic alkyl substituent;
- 11.23 (iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or
- 11.24 methoxybenzyl groups; or
- 11.25 (iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure.
- 11.26 (h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless specifically
- 11.27 excepted or unless listed in another schedule, any natural or synthetic material, compound,
- 11.28 mixture, or preparation that contains any quantity of the following substances, their analogs,
- 11.29 isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence
- 11.30 of the isomers, esters, ethers, or salts is possible:

- 12.1 (1) marijuana;
- 12.2 (2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, synthetic
12.3 equivalents of the substances contained in the cannabis plant or in the resinous extractives
12.4 of the plant, or synthetic substances with similar chemical structure and pharmacological
12.5 activity to those substances contained in the plant or resinous extract, including, but not
12.6 limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans tetrahydrocannabinol, and 3,4
12.7 cis or trans tetrahydrocannabinol;
- 12.8 (3) synthetic cannabinoids, including the following substances:
- 12.9 (i) Naphthoylindoles, which are any compounds containing a 3-(1-naphthoyl)indole
12.10 structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
12.11 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
12.12 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any
12.13 extent and whether or not substituted in the naphthyl ring to any extent. Examples of
12.14 naphthoylindoles include, but are not limited to:
- 12.15 (A) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);
- 12.16 (B) 1-Butyl-3-(1-naphthoyl)indole (JWH-073);
- 12.17 (C) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);
- 12.18 (D) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);
- 12.19 (E) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);
- 12.20 (F) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);
- 12.21 (G) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);
- 12.22 (H) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);
- 12.23 (I) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);
- 12.24 (J) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).
- 12.25 (ii) Naphthylmethylinindoles, which are any compounds containing a
12.26 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the
12.27 indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
12.28 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further
12.29 substituted in the indole ring to any extent and whether or not substituted in the naphthyl
12.30 ring to any extent. Examples of naphthylmethylinindoles include, but are not limited to:
- 12.31 (A) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);

13.1 (B) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane (JWH-184).

13.2 (iii) Naphthoylpyrroles, which are any compounds containing a 3-(1-naphthoyl)pyrrole
13.3 structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl,
13.4 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
13.5 2-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring to any
13.6 extent, whether or not substituted in the naphthyl ring to any extent. Examples of
13.7 naphthoylpyrroles include, but are not limited to,
13.8 (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).

13.9 (iv) Naphthylmethylindenes, which are any compounds containing a naphthylideneindene
13.10 structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl,
13.11 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
13.12 2-(4-morpholinyl)ethyl group whether or not further substituted in the indene ring to any
13.13 extent, whether or not substituted in the naphthyl ring to any extent. Examples of
13.14 naphthylemethylindenes include, but are not limited to,
13.15 E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).

13.16 (v) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole
13.17 structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
13.18 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
13.19 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any
13.20 extent, whether or not substituted in the phenyl ring to any extent. Examples of
13.21 phenylacetylindoles include, but are not limited to:

13.22 (A) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);

13.23 (B) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);

13.24 (C) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);

13.25 (D) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).

13.26 (vi) Cyclohexylphenols, which are compounds containing a
13.27 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic
13.28 ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
13.29 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not substituted
13.30 in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include, but are not
13.31 limited to:

13.32 (A) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);

- 14.1 (B) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol
14.2 (Cannabicyclohexanol or CP 47,497 C8 homologue);
- 14.3 (C) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]
14.4 -phenol (CP 55,940).
- 14.5 (vii) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole structure
14.6 with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl,
14.7 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl or
14.8 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any
14.9 extent and whether or not substituted in the phenyl ring to any extent. Examples of
14.10 benzoylindoles include, but are not limited to:
- 14.11 (A) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);
- 14.12 (B) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);
- 14.13 (C) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone (WIN
14.14 48,098 or Pravadoline).
- 14.15 (viii) Others specifically named:
- 14.16 (A) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
14.17 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);
- 14.18 (B) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
14.19 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);
- 14.20 (C) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]
14.21 -1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2);
- 14.22 (D) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);
- 14.23 (E) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
14.24 (XLR-11);
- 14.25 (F) 1-pentyl-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl-1H-indazole-3-carboxamide
14.26 (AKB-48(APINACA));
- 14.27 (G) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
14.28 (5-Fluoro-AKB-48);
- 14.29 (H) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);
- 14.30 (I) 8-quinolinyl ester-1-(5-fluoropentyl)-1H-indole-3-carboxylic acid (5-Fluoro PB-22);

- 15.1 (J) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-3-carboxamide
15.2 (AB-PINACA);
- 15.3 (K) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-
15.4 1H-indazole-3-carboxamide (AB-FUBINACA);
- 15.5 (L) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-
15.6 indazole-3-carboxamide(AB-CHMINACA);
- 15.7 (M) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate
15.8 (5-fluoro-AMB);
- 15.9 (N) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone (THJ-2201);
- 15.10 (O) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone
15.11 (FUBIMINA);
- 15.12 (P) (7-methoxy-1-(2-morpholinoethyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo
15.13 [2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (MN-25 or UR-12);
- 15.14 (Q) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)
15.15 -1H-indole-3-carboxamide (5-fluoro-ABICA);
- 15.16 (R) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)
15.17 -1H-indole-3-carboxamide;
- 15.18 (S) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)
15.19 -1H-indazole-3-carboxamide;
- 15.20 (T) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate;
- 15.21 (U) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1
15.22 H-indazole-3-carboxamide (MAB-CHMINACA);
- 15.23 (V) N-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-pentyl-1H-indazole-3-carboxamide
15.24 (ADB-PINACA);
- 15.25 (W) methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate (FUB-AMB);
- 15.26 (X) N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-1-(cyclohexylmethyl)-1H-Indazole-
15.27 3-carboxamide. (APP-CHMINACA);
- 15.28 (Y) quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FUB-PB-22); and
- 15.29 (Z) methyl N-[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]valinate (MMB-CHMICA).
- 15.30 (ix) Additional substances specifically named:

- 16.1 (A) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1
16.2 H-pyrrolo[2,3-B]pyridine-3-carboxamide (5F-CUMYL-P7AICA);
- 16.3 (B) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1 H-indazole-3-carboxamide
16.4 (4-CN-Cumyl-Butinaca);
- 16.5 (C) naphthalen-1-yl-1-(5-fluoropentyl)-1-H-indole-3-carboxylate (NM2201; CBL2201);
- 16.6 (D) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1
16.7 H-indazole-3-carboxamide (5F-ABPINACA);
- 16.8 (E) methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate
16.9 (MDMB CHMICA);
- 16.10 (F) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate
16.11 (5F-ADB; 5F-MDMB-PINACA); and
- 16.12 (G) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)
16.13 1H-indazole-3-carboxamide (ADB-FUBINACA).
- 16.14 (i) A controlled substance analog, to the extent that it is implicitly or explicitly intended
16.15 for human consumption.

16.16 Sec. 2. Minnesota Statutes 2018, section 152.02, subdivision 3, is amended to read:

16.17 Subd. 3. **Schedule II.** (a) Schedule II consists of the substances listed in this subdivision.

16.18 (b) Unless specifically excepted or unless listed in another schedule, any of the following
16.19 substances whether produced directly or indirectly by extraction from substances of vegetable
16.20 origin or independently by means of chemical synthesis, or by a combination of extraction
16.21 and chemical synthesis:

16.22 (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or
16.23 opiate.

16.24 (i) Excluding:

16.25 (A) apomorphine;

16.26 (B) thebaine-derived butorphanol;

16.27 (C) dextrophan;

16.28 (D) nalbuphine;

16.29 (E) nalmefene;

16.30 (F) naloxegol;

- 17.1 (G) naloxone;
- 17.2 (H) naltrexone; and
- 17.3 (I) their respective salts;
- 17.4 (ii) but including the following:
- 17.5 (A) opium, in all forms and extracts;
- 17.6 (B) codeine;
- 17.7 (C) dihydroetorphine;
- 17.8 (D) ethylmorphine;
- 17.9 (E) etorphine hydrochloride;
- 17.10 (F) hydrocodone;
- 17.11 (G) hydromorphone;
- 17.12 (H) metopon;
- 17.13 (I) morphine;
- 17.14 (J) oxycodone;
- 17.15 (K) oxymorphone;
- 17.16 (L) thebaine;
- 17.17 (M) oripavine;
- 17.18 (2) any salt, compound, derivative, or preparation thereof which is chemically equivalent
- 17.19 or identical with any of the substances referred to in clause (1), except that these substances
- 17.20 shall not include the isoquinoline alkaloids of opium;
- 17.21 (3) opium poppy and poppy straw;
- 17.22 (4) coca leaves and any salt, cocaine compound, derivative, or preparation of coca leaves
- 17.23 (including cocaine and ecgonine and their salts, isomers, derivatives, and salts of isomers
- 17.24 and derivatives), and any salt, compound, derivative, or preparation thereof which is
- 17.25 chemically equivalent or identical with any of these substances, except that the substances
- 17.26 shall not include decocainized coca leaves or extraction of coca leaves, which extractions
- 17.27 do not contain cocaine or ecgonine;
- 17.28 (5) concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid,
- 17.29 or powder form which contains the phenanthrene alkaloids of the opium poppy).

18.1 (c) Any of the following opiates, including their isomers, esters, ethers, salts, and salts
18.2 of isomers, esters and ethers, unless specifically excepted, or unless listed in another schedule,
18.3 whenever the existence of such isomers, esters, ethers and salts is possible within the specific
18.4 chemical designation:

18.5 (1) alfentanil;

18.6 (2) alphaprodine;

18.7 (3) anileridine;

18.8 (4) bezitramide;

18.9 (5) bulk dextropropoxyphene (nondosage forms);

18.10 (6) carfentanil;

18.11 (7) dihydrocodeine;

18.12 (8) dihydromorphinone;

18.13 (9) diphenoxylate;

18.14 (10) fentanyl;

18.15 (11) isomethadone;

18.16 (12) levo-alpha-acetylmethadol (LAAM);

18.17 (13) levomethorphan;

18.18 (14) levorphanol;

18.19 (15) metazocine;

18.20 (16) methadone;

18.21 (17) methadone - intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;

18.22 (18) moramide - intermediate, 2-methyl-3-morpholino-1, 1-diphenyl-propane-carboxylic
18.23 acid;

18.24 (19) pethidine;

18.25 (20) pethidine - intermediate - a, 4-cyano-1-methyl-4-phenylpiperidine;

18.26 (21) pethidine - intermediate - b, ethyl-4-phenylpiperidine-4-carboxylate;

18.27 (22) pethidine - intermediate - c, 1-methyl-4-phenylpiperidine-4-carboxylic acid;

18.28 (23) phenazocine;

- 19.1 (24) piminodine;
- 19.2 (25) racemethorphan;
- 19.3 (26) racemorphan;
- 19.4 (27) remifentanyl;
- 19.5 (28) sufentanyl;
- 19.6 (29) tapentadol;
- 19.7 (30) ~~4-Anilino-N-phenethyl-4-piperidine (ANPP)~~ 4-Anilino-N-phenethylpiperidine.

19.8 (d) Unless specifically excepted or unless listed in another schedule, any material,
19.9 compound, mixture, or preparation which contains any quantity of the following substances
19.10 having a stimulant effect on the central nervous system:

- 19.11 (1) amphetamine, its salts, optical isomers, and salts of its optical isomers;
- 19.12 (2) methamphetamine, its salts, isomers, and salts of its isomers;
- 19.13 (3) phenmetrazine and its salts;
- 19.14 (4) methylphenidate;
- 19.15 (5) lisdexamfetamine.

19.16 (e) Unless specifically excepted or unless listed in another schedule, any material,
19.17 compound, mixture, or preparation which contains any quantity of the following substances
19.18 having a depressant effect on the central nervous system, including its salts, isomers, and
19.19 salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible
19.20 within the specific chemical designation:

- 19.21 (1) amobarbital;
- 19.22 (2) glutethimide;
- 19.23 (3) secobarbital;
- 19.24 (4) pentobarbital;
- 19.25 (5) phencyclidine;
- 19.26 (6) phencyclidine immediate precursors:
- 19.27 (i) 1-phenylcyclohexylamine;
- 19.28 (ii) 1-piperidinocyclohexanecarbonitrile;
- 19.29 (7) phenylacetone.

20.1 (f) ~~Hallucinogenic substances~~ Cannabinoids:

20.2 (1) nabilone;

20.3 (2) dronabinol [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)] in an oral solution
20.4 in a drug product approved for marketing by the United States Food and Drug Administration.

20.5 Sec. 3. Minnesota Statutes 2018, section 152.02, subdivision 4, is amended to read:

20.6 Subd. 4. **Schedule III.** (a) Schedule III consists of the substances listed in this subdivision.

20.7 (b) Stimulants. Unless specifically excepted or unless listed in another schedule, any
20.8 material, compound, mixture, or preparation which contains any quantity of the following
20.9 substances having a potential for abuse associated with a stimulant effect on the central
20.10 nervous system, including its salts, isomers, and salts of such isomers whenever the existence
20.11 of such salts, isomers, and salts of isomers is possible within the specific chemical
20.12 designation:

20.13 (1) benzphetamine;

20.14 (2) chlorphentermine;

20.15 (3) clortermine;

20.16 (4) phendimetrazine.

20.17 (c) Depressants. Unless specifically excepted or unless listed in another schedule, any
20.18 material, compound, mixture, or preparation which contains any quantity of the following
20.19 substances having a potential for abuse associated with a depressant effect on the central
20.20 nervous system:

20.21 (1) any compound, mixture, or preparation containing amobarbital, secobarbital,
20.22 pentobarbital or any salt thereof and one or more other active medicinal ingredients which
20.23 are not listed in any schedule;

20.24 (2) any suppository dosage form containing amobarbital, secobarbital, pentobarbital, or
20.25 any salt of any of these drugs and approved by the food and drug administration for marketing
20.26 only as a suppository;

20.27 (3) any substance which contains any quantity of a derivative of barbituric acid, or any
20.28 salt of a derivative of barbituric acid, except those substances which are specifically listed
20.29 in other schedules;

21.1 (4) any drug product containing gamma hydroxybutyric acid, including its salts, isomers,
21.2 and salts of isomers, for which an application is approved under section 505 of the federal
21.3 Food, Drug, and Cosmetic Act;

21.4 (5) any of the following substances:

21.5 (i) chlorhexadol;

21.6 (ii) ketamine, its salts, isomers and salts of isomers;

21.7 (iii) lysergic acid;

21.8 (iv) lysergic acid amide;

21.9 (v) methyprylon;

21.10 (vi) sulfondiethylmethane;

21.11 (vii) sulfonethylmethane;

21.12 (viii) sulfonmethane;

21.13 (ix) tiletamine and zolazepam and any salt thereof;

21.14 (x) embutramide;

21.15 (xi) Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-Dihydropyridin-3-yl)
21.16 benzonitrile].

21.17 (d) Nalorphine.

21.18 (e) Narcotic drugs. Unless specifically excepted or unless listed in another schedule,
21.19 any material, compound, mixture, or preparation containing any of the following narcotic
21.20 drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities
21.21 as follows:

21.22 (1) not more than 1.80 grams of codeine per 100 milliliters or not more than 90 milligrams
21.23 per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;

21.24 (2) not more than 1.80 grams of codeine per 100 milliliters or not more than 90 milligrams
21.25 per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic
21.26 amounts;

21.27 (3) not more than 1.80 grams of dihydrocodeine per 100 milliliters or not more than 90
21.28 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized
21.29 therapeutic amounts;

22.1 (4) not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than
22.2 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized
22.3 therapeutic amounts;

22.4 (5) not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not
22.5 more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients
22.6 in recognized therapeutic amounts;

22.7 (6) not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with
22.8 one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

22.9 (f) Anabolic steroids, human growth hormone, and chorionic gonadotropin.

22.10 (1) Anabolic steroids, for purposes of this subdivision, means any drug or hormonal
22.11 substance, chemically and pharmacologically related to testosterone, other than estrogens,
22.12 progestins, corticosteroids, and dehydroepiandrosterone, and includes:

22.13 (i) 3[beta],17[beta]-dihydroxy-5[alpha]-androstane;

22.14 (ii) 3[alpha],17[beta]-dihydroxy-5[alpha]-androstane;

22.15 (iii) androstanedione (5[alpha]-androstane-3,17-dione);

22.16 (iv) 1-androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-1-ene;

22.17 (v) 3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene);

22.18 (vi) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene);

22.19 (vii) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene);

22.20 (viii) 1-androstenedione (5[alpha]-androst-1-en-3,17-dione);

22.21 (ix) 4-androstenedione (androst-4-en-3,17-dione);

22.22 (x) 5-androstenedione (androst-5-en-3,17-dione);

22.23 (xi) bolasterone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);

22.24 (xii) boldenone (17[beta]-hydroxyandrost-1,4-diene-3-one);

22.25 (xiii) boldione (androsta-1,4-diene-3,17-dione);

22.26 (xiv) calusterone (7[beta],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);

22.27 (xv) clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one);

22.28 (xvi) dehydrochloromethyltestosterone

22.29 (4-chloro-17[beta]-hydroxy-17[alpha]-methylandrost-1,4-dien-3-one);

- 23.1 (xvii) desoxymethyltestosterone (17[alpha]-methyl-5[alpha]-androst-2-en-17[beta]-ol);
- 23.2 (xviii) [delta]1-dihydrotestosterone- (17[beta]-hydroxy-5[alpha]-androst-1-en-3-one);
- 23.3 (xix) 4-dihydrotestosterone (17[beta]-hydroxy-androstan-3-one);
- 23.4 (xx) drostanolone (17[beta]hydroxy-2[alpha]-methyl-5[alpha]-androstan-3-one);
- 23.5 (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-ene);
- 23.6 (xxii) fluoxymesterone
- 23.7 (9-fluoro-17[alpha]-methyl-11[beta],17[beta]-dihydroxyandrost-4-en-3-one);
- 23.8 (xxiii) formebolone
- 23.9 (2-formyl-17[alpha]-methyl-11[alpha],17[beta]-dihydroxyandrost-1,4-dien-3-one);
- 23.10 (xxiv) furazabol
- 23.11 (17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]-furazan)13[beta]-ethyl-17[beta]
- 23.12 -hydroxygon-4-en-3-one;
- 23.13 (xxv) 4-hydroxytestosterone (4,17[beta]-dihydroxyandrost-4-en-3-one);
- 23.14 (xxvi) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxyestr-4-en-3-one);
- 23.15 (xxvii) mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one);
- 23.16 (xxviii) mesterolone (1[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one);
- 23.17 (xxix) methandienone (17[alpha]-methyl-17[beta]-hydroxyandrost-1,4-dien-3-one);
- 23.18 (xxx) methandriol (17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-5-ene);
- 23.19 (xxxi) methasterone (2 alpha-17 alpha-dimethyl-5 alpha-androstan-17beta-ol-3-one);
- 23.20 (xxxii) methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-androst-1-en-3-one);
- 23.21 (xxxiii) 17[alpha]-methyl-3[beta],17[beta]-dihydroxy-5[alpha]-androstane;
- 23.22 (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5[alpha]-androstane;
- 23.23 (xxxv) 17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-4-ene;
- 23.24 (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone
- 23.25 (17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one);
- 23.26 (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one);
- 23.27 (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9-11-trien-3-one);
- 23.28 (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-hydroxyandrost-4-en-3-one);

- 24.1 (xl) mibolerone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyestr-4-en-3-one);
- 24.2 (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone
- 24.3 (17[beta]-hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one);
- 24.4 (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one);
- 24.5 (xliii) 19-nor-4-androstenediol (3[beta],17[beta]-dihydroxyestr-4-ene;
- 24.6 (xliv) 3[alpha],17[beta]-dihydroxyestr-4-ene); 19-nor-5-androstenediol
- 24.7 (3[beta],17[beta]-dihydroxyestr-5-ene;
- 24.8 (xlv) 3[alpha],17[beta]-dihydroxyestr-5-ene);
- 24.9 (xlvi) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);
- 24.10 (xlvii) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
- 24.11 (xlviii) norbolethone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4-en-3-one);
- 24.12 (xlix) norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one);
- 24.13 (l) norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3-one);
- 24.14 (li) normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one);
- 24.15 (lii) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-2-oxa-5[alpha]-androstan-3-one);
- 24.16 (liii) oxymesterone (17[alpha]-methyl-4,17[beta]-dihydroxyandrost-4-en-3-one);
- 24.17 (liv) oxymetholone
- 24.18 (17[alpha]-methyl-2-hydroxymethylene-17[beta]-hydroxy-5[alpha]-androstan-3-one);
- 24.19 (lv) prostanazol (17 beta-hydroxy-5 alpha-androstano[3,2-C]pyrazole;
- 24.20 (lvi) stanozolol
- 24.21 (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androst-2-eno[3,2-c]-pyrazole);
- 24.22 (lvii) stenbolone (17[beta]-hydroxy-2-methyl-5[alpha]-androst-1-en-3-one);
- 24.23 (lviii) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);
- 24.24 (lix) testosterone (17[beta]-hydroxyandrost-4-en-3-one);
- 24.25 (lx) tetrahydrogestrinone
- 24.26 (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4,9,11-trien-3-one);
- 24.27 (lxi) trenbolone (17[beta]-hydroxyestr-4,9,11-trien-3-one);
- 24.28 (lxii) any salt, ester, or ether of a drug or substance described in this paragraph.

- 25.1 Anabolic steroids are not included if they are: (A) expressly intended for administration
25.2 through implants to cattle or other nonhuman species; and (B) approved by the United States
25.3 Food and Drug Administration for that use;
- 25.4 (2) Human growth hormones.
- 25.5 (3) Chorionic gonadotropin, except that a product containing chorionic gonadotropin is
25.6 not included if it is:
- 25.7 (i) expressly intended for administration to cattle or other nonhuman species; and
25.8 (ii) approved by the United States Food and Drug Administration for that use.
- 25.9 (g) Hallucinogenic substances. Dronabinol (synthetic) in sesame oil and encapsulated
25.10 in a soft gelatin capsule in a United States Food and Drug Administration approved product.
- 25.11 (h) Any material, compound, mixture, or preparation containing the following narcotic
25.12 drug or its salt: buprenorphine.